[{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Molecular Templates","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Molecular Templates"},{"orgOrder":0,"company":"Grupo Espanol de Tumores Neuroendocrinos","sponsor":"Molecular Templates | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol de Tumores Neuroendocrinos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Tumores Neuroendocrinos \/ Molecular Templates | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol de Tumores Neuroendocrinos \/ Molecular Templates | Pfizer Inc"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Molecular Templates","highestDevelopmentStatusID":"6","companyTruncated":"Scripps Health \/ Molecular Templates"},{"orgOrder":0,"company":"Alliance for Clinical Trials in Oncology","sponsor":"National Cancer Institute | Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Alliance for Clinical Trials in Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Molecular Templates","highestDevelopmentStatusID":"6","companyTruncated":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Molecular Templates"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ EMD Serono"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"SARC Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Molecular Templates \/ SARC Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Templates \/ SARC Foundation"},{"orgOrder":0,"company":"Maastricht Radiation Oncology","sponsor":"Molecular Templates | Zuyderland Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Maastricht Radiation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht Radiation Oncology \/ Molecular Templates | Zuyderland Medical Centre","highestDevelopmentStatusID":"6","companyTruncated":"Maastricht Radiation Oncology \/ Molecular Templates | Zuyderland Medical Centre"},{"orgOrder":0,"company":"Merck Group","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Molecular Templates","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Molecular Templates"},{"orgOrder":0,"company":"Merck Group","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Molecular Templates","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Molecular Templates"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"ImmunoGenesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ ImmunoGenesis","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ ImmunoGenesis"},{"orgOrder":0,"company":"Sarcoma Alliance for Research through Collaboration","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sarcoma Alliance for Research through Collaboration","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Alliance for Research through Collaboration \/ Molecular Templates","highestDevelopmentStatusID":"1","companyTruncated":"Sarcoma Alliance for Research through Collaboration \/ Molecular Templates"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Molecular Templates","highestDevelopmentStatusID":"10","companyTruncated":"ImmunoGenesis \/ Molecular Templates"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Molecular Templates","highestDevelopmentStatusID":"10","companyTruncated":"ImmunoGenesis \/ Molecular Templates"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Agenus"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Evofosfamide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : IMGS-101 (evofosfamide) is a DNA inhibitor, which is being evaluated for the treatment of rmetastatic castration-resistant prostate cancer, pancreatic, & HPV(-) head & neck tumors.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 06, 2025

                          Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University Health Network, Toronto

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          University Health Network, Toronto

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : ImmunoGenesis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 20, 2025

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Agenus

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 31, 2017

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : MD Anderson Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Sarcoma Alliance for Research through Collaboration

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Sarcoma Alliance for Research through Collaboration

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcoma.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 18, 2016

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Molecular Templates

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Maastricht Radiation Oncology

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Maastricht Radiation Oncology

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Esophageal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          November 06, 2015

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Molecular Templates | Zuyderland Medical Centre

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 05, 2015

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Molecular Templates

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Grupo Espanol de Tumores Neuroendocrinos

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Grupo Espanol de Tumores Neuroendocrinos

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 30, 2015

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Molecular Templates | Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          October 02, 2014

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Molecular Templates

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : TH-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 21, 2014

                          Lead Product(s) : Evofosfamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : EMD Serono

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank